October 1, 2018

G1 Therapeutics, Inc.

IPO in May 2017 (NASDAQ: GTHX).

Developer of novel, small-molecule therapies for the treatment of cancer designed to address significant unmet needs in the treatment of cancer. The company's small-molecule therapies focus on cyclin-dependent kinases and CDKs, a family of proteins that play an important role in the growth and proliferation of cells, enabling the medical industry to treat cancer.